This month’s focus on pharmaphorum is clinical trials, so who better to share their view on global clinical trials than Zheng Su, Editor-in-Chief of the Contemporary Clinical Trials journal.

NetraMark Holdings ( ($TSE:AIAI) ) just unveiled an update. NetraMark has announced the launch of NetraAI 2.0, an advanced platform aimed at ...

Throughout our clinical trials month, many different experts within this field have been sharing their opinions. Today we hear from Jeremy Spivey about clinical trial outsourcing, and whether ...

Progression-free survival (PFS) in oligometastatic prostate cancer improved significantly with metastasis-directed therapy ...

Seventy six randomised controlled trials were identified, 28 of which satisfied the minimum criteria for meta-analysis. The evidence suggests that extracorporeal shock wave therapy is not beneficial ...

New drugs for early Alzheimer’s disease may allow people to live without help for up to 39 additional months, a new study estimates. But experts urge caution.

Advertisement Article continues below this ad Yet, this lack of bespoke options is more or less the reality of medicine today. Despite the many biological differences between people of different ...

Vistagen Therapeutics' Q3 2025 earnings reveal progress on Phase 3 trials for social anxiety drug fasedienol, innovative therapies, and strong ...

SCOPE Conference (Summit for Clinical Ops Executives), held last week in Orlando, FL, brought together more than 4,500 industry ...

In a systematic review and meta-analysis of trials of non-vitamin K oral anticoagulants vs. single antiplatelet therapy, ...